|
gptkbp:instanceOf
|
gptkb:antidepressant
|
|
gptkbp:approvedBy
|
1974
|
|
gptkbp:ATCCode
|
N06AA21
|
|
gptkbp:CASNumber
|
10362-21-1
|
|
gptkbp:category
|
gptkb:norepinephrine_reuptake_inhibitor
secondary amine
anthracenes
|
|
gptkbp:chemical_compound
|
C20H23N
|
|
gptkbp:contraindication
|
history of seizures
recent myocardial infarction
|
|
gptkbp:developedBy
|
gptkb:Ciba-Geigy
|
|
gptkbp:eliminationHalfLife
|
43-60 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:IUPACName
|
3-(9,10-dihydro-9,10-ethanoanthracen-9-yl)-N-methylpropan-1-amine
|
|
gptkbp:KEGGID
|
D08206
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:norepinephrine_reuptake_inhibitor
|
|
gptkbp:meltingPoint
|
186-188°C
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
277.41 g/mol
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:proteinBinding
|
88%
|
|
gptkbp:PubChem_CID
|
4026
3888
CHEMBL1407
DB00574
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:orthostatic_hypotension
constipation
weight gain
seizures
drowsiness
dry mouth
|
|
gptkbp:synonym
|
gptkb:Ludiomil
|
|
gptkbp:UNII
|
L0IYT1Z353
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
anxiety associated with depression
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Maprotiline
|